INC.

IBC Launches Full Range of Best-in-Class Molecular Recognition Technology™ (MRT™) Flowsheets for Highly Selective Separations of Key Radionuclides and Preparation of Novel Chelating Agents for Radionuclide Incorporation into Radiopharmaceuticals USA – English India – English

by

Development of multiple anticancer drugs with radioisotopes is in progress Lu-177, Y-90, Cu-67, Ra-223, Ac-225, Pb-212 and At-211 have licensed products or are in clinical trials IBC’s state-of-the-art MRT™ separation and chelation technologies facilitate production of radiopharmaceuticals based on these and other medical radioisotopes Radioisotopes are separated at up to 99.99% purity and 99.9+% recovery … Read more

Veravas Launches Groundbreaking VeraBIND Technology for Ultra-Sensitive Assays and Matrix Free Sample Analysis

by

Revolutionary bead-based technology enables reliable biomarker detection in challenging samples, transforming clinical diagnostic performance and research workflows AUSTIN, Texas, June 20, 2023 /PRNewswire/ — Today, Veravas, a leading innovator in clinical diagnostics, announced the launch of its groundbreaking VeraBIND™ (Biomarker Isolation and N-richment for Detection) technology. With millions of assays conducted daily in clinical laboratories … Read more

Delcath Systems Appoints Vojislav Vukovic as Chief Medical Officer

by

NEW YORK, June 20, 2023 /PRNewswire/ — Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr.  Vojislav “Vojo” Vukovic as its new Chief Medical Officer (CMO). Dr. Vukovic is an experienced … Read more

Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis

by

–  First FDA Breakthrough Therapy Designation granted for AdenoVerse immunotherapy platform; designation prioritizes PRGN-2012 as a potential treatment for RRP ––  Designation based on positive Phase 1 clinical data that showed 50% of patients were “surgery-free” (Complete Response) after PRGN-2012 treatment with a minimum follow up of 12 months post-treatment – GERMANTOWN, Md. , June 20, … Read more

Minghui Pharmaceutical Inc. Announces First Patient Dosing in Phase 1 Clinical Studies of Both the Antibody-Drug Conjugate Programs Targeting TROP-2 or B7-H3 Respectively, for Treatment of Advanced or Metastatic Solid Tumors

by

SHANGHAI and HANGZHOU, China and WILMINGTON, Del., June 20, 2023 /PRNewswire/ — Minghui Pharmaceutical, Inc., a leading clinical-stage biopharmaceutical company, announced today that the first dosing has been completed in two phase 1 clinical studies evaluating MHB036C and MHB088C. The studies aim to determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D), … Read more

Arcellx Announces Clinical Hold for its iMMagine-1 Phase 2 Clinical Program

by

— FDA has provided clearance to the company to continue dosing patients who have already undergone lymphodepletion — REDWOOD CITY, Calif., June 19, 2023 /PRNewswire/ — Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, announced today that it has … Read more

Avanos Medical, Inc. Announces Agreement to Acquire Diros Technology Inc.

by

Unique tined-probe technology further differentiates Avanos portfolio ALPHARETTA, Ga., June 19, 2023 /PRNewswire/ — Avanos Medical, Inc. (NYSE: AVNS) today announced it has entered into a definitive agreement to acquire Diros Technology Inc., a leading manufacturer of innovative radiofrequency (RF) products used to treat chronic pain conditions. Based in Toronto, Canada, Diros Technology has been … Read more

Novavax est prêt à fournir un vaccin monovalent protéinique contre le virus XBB COVID conformément à la recommandation du VRBPAC de la FDA pour l’automne USA – Français USA – English APAC – English USA – Deutsch USA – español USA – English USA – English APAC – English

by

Novavax a développé un vaccin candidat monovalent protéinique contre le virus XBB.1.5 COVID et le produit à l’échelle commerciale avec l’intention de le lancer sur le marché lors de la campagne de vaccination prévue à l’automne Novavax a partagé des données démontrant que son vaccin candidat XBB.1.5 COVID induit des réponses immunitaires fonctionnelles aux sous-variants … Read more

Millar Steers PV Loop Technology and Customers into the Future by Combining Market Leading Catheter Solutions with Transonic Scisense Systems

by

HOUSTON, June 19, 2023 /PRNewswire/ — Millar, the industry leader in research pressure measurements and global OEM solutions partner, announces that it will be guiding pressure-volume (PV) loop technology into the future by combining its market-leading catheter solutions with Transonic Scisense’s Admittance-based pressure-volume (PV) loop systems. To support Transonic Scisense’s exit from the life sciences … Read more

Nippon Express Europe a participé pour la première fois à LogiPharma 2023

by

TOKYO, 19 juin 2023 /PRNewswire/ — Nippon Express Europe GmbH, une société du groupe NIPPON EXPRESS HOLDINGS, INC., a participé pour la première fois au salon LogiPharma 2023 qui s’est tenu à Lyon, en France, du mardi 25 avril au jeudi 27 avril. Logo : https://kyodonewsprwire.jp/img/202306136298-O1-VPF88v28 Photo : https://cdn.kyodonewsprwire.jp/prwfile/release/M103866/202306136298/_prw_PI2fl_NJKJYRjE.jpg? _ga=2.3372912.1997240702.1686531031-1438572707.1685531252 LogiPharma 2023 est l’un des plus grands salons pharmaceutiques internationaux, axé sur les … Read more